BillionToOne
- 25/06/2024
- Series D
- $130,000,000
BillionToOne is a precision diagnostics company with the mission to make molecular diagnostics more accurate, efficient, and accessible. Our proprietary molecular counting platform can accurately count DNA molecules at the single-count level to help improve disease detection.
- Industry Biotechnology Research
- Website https://billiontoone.com/
- LinkedIn https://www.linkedin.com/company/billiontoone/
Related People
Oguzhan Atay, PhDCo Founder
CEO of BillionToOne, a YC S17 company. Globally, more than 3,000,000 babies are born every year with serious genetic defects. Backed by prominent angel investors and VCs, BillionToOne is developing a prenatal genetic test for every expecting mother. Our novel method can detect genetic disorders, including certain single-gene diseases such as thalassemia, through a sequencing of maternal blood.
Previously:
PhD from Stanford: Quantitative Cell Biology. Developed mathematical models and machine learning algorithms to extract meaningful information from TB-scale noisy data, obtained by imaging of genetically manipulated strains.
Bachelor's from Princeton (PBK and summa cum laude): Molecular Biology with minors in CS, Applied Mathematics, and Physics.
Other:
Published in Cell, Cell Systems, Plos One, Molecular Biology of the Cell, and Journal of Cell Biology.
Proficient in Big Data stack (including Spark) for advanced analytics and machine learning
Experience with full-stack software development
Ranked 1st in Turkish University Entrance Exam in 2008 (>1.5M test takers)